Utibron Neohaler OverviewIndacaterol (INN) is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez Breezhaler on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is l...
Read more Utibron Neohaler Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Indacaterol
Recent Utibron Neohaler Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
Indacaterol + Glycopyrrolate
- Powder: 15.6mcg/inh + 27.5mcg/inh, 27.5mcg
NDC Database Records for Utibron Neohaler: (2 results)Sorted by National Drug Code
- 0078-0664 Utibron Neohaler Respiratory (Inhalation) Capsule by Novartis Pharmaceuticals Corporation
- 63402-681 Utibron Neohaler Respiratory (Inhalation) Capsule by Sunovion Pharmaceuticals Inc.
Drugs with one or more similar ingredients: (12 results)
- INDACATEROL + GLYCOPYRROLATE
- ARCAPTA Indacaterol Maleate
- BEVESPI AEROSPHERE Glycopyrrolate + Formoterol Fumarate1 discussion
- CUVPOSA Glycopyrrolate
- GLYCOPYRROLATE 12 discussions
- GLYCOPYRROLATE + FORMOTEROL FUMARATE
- GLYRX-PF Glycopyrrolate
- INDACATEROL MALEATE 1 discussion
- LONHALA MAGNAIR KIT Glycopyrrolate
- ROBINUL Glycopyrrolate1 discussion
- ROBINUL INJECTABLE Glycopyrrolate
- SEEBRI NEOHALER Glycopyrrolate